For instance, siRNA‐loaded nanocarriers targeting oncogenes like AEG‐1 have demonstrated potent tumor‐suppressive effects in osteosarcoma animal models; however, concerns including off‐target toxicity and unintended immune activation continue to hinder their clinical application [553]. This evidence concerns the gene MTDH and osteosarcoma.